

Isolation of a specific element from a molecular library

Keywords

High-throughput screening, genomic libraries, expression libraries, peptide libraries, panning, "gigascreening", liposomes

Competitiveness

Fields of application include but are not limited to

- production of industrially applicable enzymes and antibodies,
- development of novel highly specific therapeutics and diagnostics,
- quick production of active and passive vaccines for emergent diseases (from Ebola and similar «oddballs» to new variants of flu),
- affordable personalized therapy, e. g. of cancer,
- means for the therapy of diseases caused by highly adaptive agents, e. g. AIDS,
- «Drug Delivery Systems» such as the bdellosomes of the German patent application DE102007005191.5 (Flaig & Fricker) which are capable of releasing drugs specifically to diseased cells or pathogenic organisms,
- approaches having deeper impact on cellular events such as the possibilities arising from the theriomimetic peptides of DE102007005192.3 (Flaig & Lange-Flaig),
- and many more.

No comparable products or developments known.

IP Rights

German patent application DE 10 2008 062 965.0.

Origin

Original research conducted by Equinoctium GbR

Technology

A system for identification of interaction partners or creation of high-affinity binding molecules such as antibody-like structures, using liposomes in lieu of microwell in order to boost throughput and allowing the screening of billions of candidate molecules per run.

About Equinoctium Biotech GbR

Green biotechnology: Nitrogen-autotrophic plants with increased uptake of light energy, salt tolerance and resistance to heat, cold and drought.

High-throughput screening.

Suitable Industries

Pharmaceutics, biotech, instrumentation

Development

Type of Collaboration

Category

Diagnostics & Diagnostic Methods or Assays

Contactperson

Dr. Dr. Rüdiger Marcus Flaig
rmf@equinoctium.org
+49-8141-81825-1

Provider

Equinoctium Biotech GbR
Ringstraße 22
D-82223 Eichenau
Germany